-$1.18 Earnings Per Share Expected for Zymeworks Inc. (NYSE:ZYME) This Quarter

Equities analysts predict that Zymeworks Inc. (NYSE:ZYME) will announce earnings of ($1.18) per share for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Zymeworks’ earnings, with the highest EPS estimate coming in at ($1.01) and the lowest estimate coming in at ($1.38). Zymeworks posted earnings per share of ($1.43) in the same quarter last year, which indicates a positive year over year growth rate of 17.5%. The company is scheduled to announce its next quarterly earnings results on Tuesday, November 2nd.

On average, analysts expect that Zymeworks will report full-year earnings of ($4.58) per share for the current fiscal year, with EPS estimates ranging from ($5.00) to ($4.07). For the next fiscal year, analysts forecast that the company will post earnings of ($4.76) per share, with EPS estimates ranging from ($5.08) to ($4.24). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Zymeworks.

Zymeworks (NYSE:ZYME) last released its earnings results on Wednesday, August 4th. The company reported ($1.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.05) by ($0.26). The firm had revenue of $1.77 million for the quarter, compared to analyst estimates of $7.26 million. Zymeworks had a negative return on equity of 57.78% and a negative net margin of 1,073.23%.

ZYME has been the subject of a number of research analyst reports. Raymond James set a $74.00 price objective on shares of Zymeworks and gave the company a “strong-buy” rating in a research report on Monday, September 13th. Zacks Investment Research cut shares of Zymeworks from a “hold” rating to a “strong sell” rating in a research note on Wednesday, August 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $44.00 target price on shares of Zymeworks in a research note on Monday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Zymeworks currently has an average rating of “Buy” and a consensus target price of $50.13.

In other Zymeworks news, CEO Ali Tehrani sold 3,800 shares of the company’s stock in a transaction dated Thursday, July 15th. The shares were sold at an average price of $36.00, for a total transaction of $136,800.00. Following the sale, the chief executive officer now directly owns 264,125 shares of the company’s stock, valued at $9,508,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 5.14% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of ZYME. FMR LLC grew its stake in Zymeworks by 331.4% during the first quarter. FMR LLC now owns 2,401,897 shares of the company’s stock worth $38,863,000 after buying an additional 1,845,142 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Zymeworks by 86.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 22,938 shares of the company’s stock worth $1,084,000 after purchasing an additional 10,663 shares in the last quarter. State of New Jersey Common Pension Fund D lifted its position in shares of Zymeworks by 24.3% during the first quarter. State of New Jersey Common Pension Fund D now owns 58,641 shares of the company’s stock worth $1,852,000 after purchasing an additional 11,480 shares in the last quarter. North Growth Management Ltd. lifted its position in shares of Zymeworks by 18.4% during the first quarter. North Growth Management Ltd. now owns 58,000 shares of the company’s stock worth $1,835,000 after purchasing an additional 9,000 shares in the last quarter. Finally, Swiss National Bank lifted its position in shares of Zymeworks by 1.6% during the first quarter. Swiss National Bank now owns 78,600 shares of the company’s stock worth $2,482,000 after purchasing an additional 1,200 shares in the last quarter. 77.91% of the stock is currently owned by hedge funds and other institutional investors.

Shares of ZYME traded down $1.34 during trading hours on Thursday, reaching $29.76. 843,540 shares of the company traded hands, compared to its average volume of 475,930. The stock’s fifty day moving average is $33.24 and its 200 day moving average is $32.75. The stock has a market cap of $1.38 billion, a P/E ratio of -6.82 and a beta of 0.98. Zymeworks has a 1-year low of $24.82 and a 1-year high of $59.03.

Zymeworks Company Profile

Zymeworks, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S.

Further Reading: What is a Market Correction?

Get a free copy of the Zacks research report on Zymeworks (ZYME)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zymeworks (NYSE:ZYME)

Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.